NEW YORK (GenomeWeb) – Melanoma test development firm DermTech is pulling its proposed initial public offering.

The La Jolla, Calif.-based firm filed a request with the US Securities and Exchange Commission on Thursday saying it seeks an "immediate withdrawal" of its Form S-1 "as it has determined not to proceed with an offering at this time." It did not provide a reason for the withdrawal.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

CNBC reports that Amazon invested in the startup Grail as it sees an opportunity for its cloud computing company in genomics.

Lawrence Krauss writes at Slate that science is needed for good public policy and should not be ignored.

Researchers are working on re-making the yeast genome from scratch, according to the Associated Press.

In Cell this week: functional profiling of Plasmodium genome, a self-inactivating rabies virus, and more.